StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.58 | $0.54 | -6.59% | 0.3M |
| 05-15 | $0.53 | $0.50 | -5.54% | 0.2M |
| 05-18 | $0.49 | $0.48 | -2.24% | 0.2M |
| 05-19 | $0.47 | $0.47 | +0.53% | 0.0M |
| 05-20 | $0.46 | $0.47 | +1.47% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $8.86M | $37.06M | $27.83M | $18.34M |
Operating Income | $-3.04M | $-14.75M | $-10.36M | $-7.50M |
Net Income | $-5.13M | $-8.20M | $-2.70M | $469.00K |
EPS (Diluted) | $-0.08 | $-0.13 | $-0.04 | $0.01 |
Total Assets | $40.56M | $44.18M | $45.75M | $47.99M |
Total Liabilities | $38.37M | $38.28M | $36.73M | $36.40M |
Cash & Equivalents | $4.81M | $6.25M | $7.54M | $10.20M |
Free Cash Flow OCF − CapEx | $-1.17M | $-12.54M | $-7.61M | $-5.01M |
Shares Outstanding | 62.73M | 62.80M | 62.79M | 62.61M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.